---
title: "Morgan Stanley Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294841732.md"
description: "Morgan Stanley analyst Terence Flynn maintained a Hold rating on Crispr Therapeutics AG (CRSP) with a $60 price target. This follows a Hold from TD Cowen, while William Blair reiterated a Buy rating for the stock."
datetime: "2026-08-04T14:26:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294841732.md)
  - [en](https://longbridge.com/en/news/294841732.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294841732.md)
---

# Morgan Stanley Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Crispr Therapeutics AG, with a price target of $60.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Flynn covers the Healthcare sector, focusing on stocks such as Biogen, Gilead Sciences, and Johnson & Johnson. According to TipRanks, Flynn has an average return of 10.0% and a 57.40% success rate on recommended stocks.

In addition to Morgan Stanley, Crispr Therapeutics AG also received a Hold from TD Cowen’s Tyler Van Buren in a report issued yesterday. However, today, William Blair reiterated a Buy rating on Crispr Therapeutics AG (NASDAQ: CRSP).

### Related Stocks

- [CRSP.US](https://longbridge.com/en/quote/CRSP.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Brave Asset Management Inc. Cuts Stake in CRISPR Therapeutics AG $CRSP](https://longbridge.com/en/news/295199690.md)
- [Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts](https://longbridge.com/en/news/290700939.md)
- [bit.bio launches ioScreen CRISPR screening service for human iPSC-derived cell models](https://longbridge.com/en/news/295776409.md)
- [Morgan Stanley lifts PVA TePla voting rights to 13.62% from 12.28%](https://longbridge.com/en/news/295748848.md)
- [DZ BANK AG Reaffirms Their Buy Rating on Daimler Truck Holding AG (DTG)](https://longbridge.com/en/news/295478361.md)